___

• Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ et al "Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial". Cancer 2006; 107 : 345- 351
• ‘Gleevec Holds Potential As First Drug To Successfully Treat Neurofibromatosis’ Scientists Report October 31, 2008
• Tapper EB, Knowles D, Heffron T et al. "Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience Transplant Proc 2009; 41 : 1969-1971 condition".
• Takimoto CH, Calvo E. İn: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ editors. ‘’Principles of Oncologic Pharmacotherapy’’ Cancer Management: A Multidisciplinary Approach. 11 ed. UBM Medica. 2008. Bhushan N. ‘’c-Abl Tyrosine kinase and inhibition by the cancer drug imatinib’’ J Nutr 2007; 137: 1518-1523
• Gambacorti-Passerini CB, Gunby RH, Piazza R et al. "Molecular mechanisms of resistance to imatinib in Philadelphia- chromosome-positive Lancet Oncol 2003; 4 : 75-85. leukaemias".
• Druker BJ, Tamura S, Buchdunger E et al. ‘’Effects of a selective inhibitor of the Abl tyrosine kinaseon the growth of Bcr- Abl positive cells’’. Nat Med 1996; 5: 561- 566.
• Savage DG and Antman KH .’’Imatinib mesylate-A new oral targeted therapy ’’. N Engl J Med 2002; 346: 683-693.
• E Pennacchioli, C Colombo, M Berselli et al. ‘’Update on management of GİST and postsurgical use of imatinib’’. Open Access Surgery 2010; 3: 63–71
• Kerkelä R, Grazette L, Yacobi R et al. "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate". Nat Med 2006; 12 : 908-916.
• Shima H, Tokuyama M, Tanizawa A et al. "Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia". J Pediatr 2011; 159: 676-681 11. Nardi V, Azam and implications of ‘’Mechanisms imatinib resistance mutations in BCR- ABL’’. Curr Opin Hematol 2004;11: 35- 43.
• Copland M, Hamilton A, Elrick LJ et al. ‘’Dasatinib targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction’’.Blood 2006; 107: 4532-4539. 13. Jorgensen HG, Holyoake TL. ‘’Characterization of cancer stem cells in chronic myeloid leukaemia ’’. Biochem Soc Trans 2007; 35: 1347-1351.
• Gambacorti-Passerini CB, Gundy RH, Piazza R et al. ‘’Molecular mechanisms of resistance to imatinib in Philadelphia- chromosome-positive Lancet Oncol 2003; 4: 75-85 leukaemias’’.
• Larghero J, Mahon FX, Madeleine- Chambrin I et al. ‘’Elevated levels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevac (STI571, imatinib) in vitro and are associated with primary resistance in vivo’’. Presented at the 43rd annual meeting of the American Society of Hematology 2001, Orlando
• Yamada O, Ozaki K, Furukawa T. ‘’Activation of STAT 5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1’’. Cell Signal 2011; 23: 1119-1127
• Shah NP, Nicoll JM, Nagar B et al. ‘’Multiple BCR⁄ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic myeloid leukaemia ‘’. Cancer Cell 2002; 2: 117-125
• Hughes T. ‘’Mechanisms of resistance, common BCR-ABL mutations, and monitoring response to treatment in CML’’. Medscape 2008. Accessed August 17, 2011
• Gorre ME, Mohammed M, Ellwood K et al. ‘’Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification’’.Science 2001; 293: 876-880.
• Branford S, Rudzki Z, Walsh S et al. ‘’Detection of BCR⁄ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis’’. Blood 2003; 102: 276-283.
• Quinta´s Cardama A, Kantarjian H, Cortes J. ‘’Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia ’’. Cancer Control 2009; 16: 122-131.
• Bartholomeusz G, Talpaz M, Kapuria V et al. ‘’Activation of a novel Bcr⁄Abl destruction pathway by WP1130 induces apoptosis leukemia cells’’. Blood 2007; 109: 3470- 3478 myelogenous
• von Bubnoff N, Schneller F, Peschel C, et al. ‘’BCRABL gene mutations in relation Philadelphia-chromosome-positive leukemia to STI-571; a prospective study’’. Lancet 2002; 359:487-491. of
• Hayette S, Chabane K, Tchirkov A et al. ‘’Detection insertions in the BCR⁄ABL kinase domain in an imatinib resistant but dasatinib sensitive patient with bi-phenotypic acute leukemia’’. Haematologica 2009; 94: 1324-1326. nucleotide 25. Azam M, Latek R, Daley G. ‘’Mechanisms of autoinhibition and STI- 571 ⁄ imatinib resistance revealed by mutagenesis of BCR-ABL’’. Cell 2003; 112: 831-843.
• Hagop M. Kantarjian, Moshe Talpaz et al. ‘’Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy myelogenous 2003;101:473-475 chronic Blood leukemia’’
• Weisberg E, Manley PW, Breitenstein W. ‘’Characterization of AMN107, a selective inhibitor of native and mutant BCR⁄ ABL’’. Cancer Cell 2005; 7: 129-141.
• Shah NP, Tran C, Lee FY et al. ‘’Overriding imatinib resistance with a novel ABL kinase inhibitor’’. Science 2004; 305: 399- 401.
• O’Hare T, Shakespeare W, Zhu X et al. ‘’AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcome mutation-based resistance’’. Cancer Cell 2009; 16: 401-412.
• Giles FJ, Cortes J, Jones D et al. ‘’MK- 0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation’’. Blood 2007; 109: 500-502